April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Poloxamer Improves the Duration of Action of Suramab to Inhibit Corneal Angiogenesis
Author Affiliations & Notes
  • Emiliano S. Lopez
    Research Area, Universidad Austral, Nanomedicine & Vision Group,, Capital Federal, Argentina
  • Juan Croxatto
    Ocular Pathology, Fundación Oftalmológica Argentina, Capital Federal, Argentina
  • Juan E. Gallo
    Ophthalmology, Hospital Universitario Austral, Nanomedicine & Vision Group,, Pilar, Argentina
  • Nanomedicine & Vision Group, Universidad Austral,Buenos Aires, Argentina
    Research Area, Universidad Austral, Nanomedicine & Vision Group,, Capital Federal, Argentina
  • Footnotes
    Commercial Relationships  Emiliano S. Lopez, None; Juan Croxatto, None; Juan E. Gallo, None
  • Footnotes
    Support  Conicet
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6383. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emiliano S. Lopez, Juan Croxatto, Juan E. Gallo, Nanomedicine & Vision Group, Universidad Austral,Buenos Aires, Argentina; Poloxamer Improves the Duration of Action of Suramab to Inhibit Corneal Angiogenesis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6383.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : In previous studies we showed the antiangiogenic effect of Suramab (3mg/kg of bevacizumab and 10mg/kg of suramin) in an animal model of corneal neovascularization. In the present study we aimed at evaluating the effect of Poloxamer (a polymer) to prolong the effect of suramab.

Methods: : Corneal NV was induced in three groups of Sprague Dawley rats, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Group one (n=6) was treated after injury with subconjunctival Suramab + Poloxamer (SP). Group two (n=6) was treated with subconjunctival Suramab (S). Group three (n=5) received no treatment. At 15 days of follow up animals were sacrificed and perfused with black drawing ink. Digital photographs were taken and the area of neovascularisation (ANV) was calculated using the jimage programme.

Results: : In the two treated groups the ANV was remarkably inferior compared to that found in controls (p<0,05). Besides, the ANV was lower in SP animals compared to that seen in S animals. No adverse effects were observed at 15 days of follow-up.

Conclusions: : Duration of the effect with SP was longer than that obtained with S. The presence of Poloxamer, known to modulate control release of biological agents, seems to have a favorable effect on suramab subconjunctivally administered. Further experiments are necessary to confirm the usefulness of this combination in ocular therapy.

Keywords: cornea: clinical science • neovascularization • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×